More Medicare plans cover Humira biosimilars, but do little to encourage patient use

Taking stock of the drug industry, from the lab to the medicine chest

May 8, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

David J. Phillip/AP STAT+ | More Medicare plans cover Humira biosimilars, but do little to encourage patient use A report from the inspector general of HHS examines the latest trends since several biosimilar versions of Humira were launched in the U.S. in 2023. By Ed Silverman STAT+ | New CBER Director Vinay Prasad praises evidence, FDA reviewers in first speech to staff The CBER director sounded very different from his online firebrand persona. He struck a humble, self-deprecating, and even earnest tone in his speech to FDA staff. By Lizzy Lawrence Inside the world of internet peptides Social media influencers hype risky peptides like BPC-157 and melanotan. Experts warn of dangers as unregulated compounds surge in wellness circles. By Alex Hogan Sarah Gonzalez for STAT STAT+ | Insitro, an AI biotech founded by Daphne Koller, lays off staff Insitro, which has branded itself as a grownup among AI biotechs, lays off staff before launching any clinical trials of new drugs. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser